Can we convert CRC-MSS tumors to be responsive to immunotherapy?
Monday, 30 November 2026, 3:00 pm
Michael Bergmann
Michael Bergmann argues that MSS colorectal cancers may be made responsive to immunotherapy by reprogramming their immunologically “cold” tumour microenvironment. Combining immunotherapy with treatments such as chemoradiation or oncolytic viruses may enhance tumour immunogenicity and T-cell infiltration. The goal is to turn an immune-resistant tumour into one that the immune system can recognise and attack.
About Michael Bergmann
Michael Bergmann is a Professor of Surgery at the Medical University of Vienna and a specialist in visceral and colorectal surgery. His research focuses on colorectal cancer immunology, particularly the mechanisms underlying immune resistance in microsatellite-stable tumours and strategies to overcome it. His translational work bridges surgical oncology with immunotherapy, including neoadjuvant treatment, tumour-microenvironment modulation and oncolytic virotherapy.
European Colorectal Congress 2026
See the full program and secure your seat.
You might also be interested in
-
Near complete response: what to do now?
Geerard Beets contests the notion that a near-complete response should invariably result in TME, as further tumour regression remains a possibility.
-
Low anterior resection syndrome and trajectories
Low anterior resection syndrome (LARS) is not a static complication but a dynamic, individual trajectory that can evolve over years after rectal…
-
The Anatomy of Successful Mesocolic Excision: Embryological Planes and Vascular Variations
Mehmet Ayhan Kuzu argues that successful complete mesocolic excision starts with embryology: meticulous dissection along the natural visceral–parietal fascial planes preserves an…